NEW YORK, Dec. 05, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on AEMD, NVCN, RWLK, and AVGR which is a click away at http://www.wallstequities.com/registration. WallStEquities.com has its attention directed to the Medical Appliances and Equipment space, which primarily offers equipment and devices that are designed for diagnosing, monitoring, and treating patients in health care systems worldwide. Four stocks have been lined up for evaluation, and they are Aethlon Medical Inc. (NASDAQ : AEMD ), Neovasc Inc. (NASDAQ : NVCN ), ReWalk Robotics Ltd (NASDAQ : RWLK ), and Avinger Inc. (NASDAQ : AVGR ). Get you free stock reports on these stock by registering now on Wall St. Equities at: http://www.wallstequities.com/registration
On Monday, shares in San Diego, California-based Aethlon Medical Inc. recorded a trading volume of 97,529 shares. The stock ended the session 0.98% higher at $1.03. The Company's shares have gained 5.28% in the last one month. The stock is trading 1.94% below its 50-day moving average. Moreover, shares of Aethlon Medical, which focuses on creating devices that address unmet medical needs in health and biodefense worldwide, have a Relative Strength Index (RSI) of 55.06.
On November 20th, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $3 per share.
On November 29th, 2017, Aethlon Medical announced the appointment of Charles "Chuck" J. Fisher, Jr., MD as Chairman of its Board of Directors. Dr. Fisher is a physician scientist with a distinguished career in both academia and industry spanning over 30 years. Prior to joining industry, he served as Head of the Section of Critical Care Medicine at The Cleveland Clinic Foundation. Get started with a complimentary subscription and access to the free report on AEMD at: http://www.wallstequities.com/registration/?symbol=AEMD
Richmond, Canada headquartered Neovasc Inc.'s stock closed the day 6.28% lower at $0.73 with a total trading volume of 365,389 shares. The stock is trading 45.70% below their 50-day moving average. Shares of the Company, which develops, manufactures, and markets cardiovascular products worldwide, have an RSI of 24.38.
On November 17th, 2017, Neovasc announced the closing of its previously announced underwritten offering of 6,609,588 Series A units and 19,066,780 Series B units at a price of US$1.46 per unit for gross proceeds of approximately US$37,487,497, before deducting the underwriting discounts and commissions and other estimated offering expenses, payable by the Company. Concurrent with the offering, Neovasc completed a private placement for the sale of US$32,750,000 aggregate principal amount of senior secured convertible notes and Series E warrants of the Company for gross proceeds of US$27,837,500. Free research on NVCN can be accessed at: http://www.wallstequities.com/registration/?symbol=NVCN
Shares in Israel headquartered ReWalk Robotics Ltd recorded a trading volume of 542,086 shares, which was higher than their three months average volume of 475,060 shares. The stock ended yesterday's trading session 4.35% lower at $1.10. The Company's shares are trading below their 50-day moving average by 20.59%. Furthermore, shares of ReWalk Robotics, which designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions, have an RSI of 36.56.
On November 30th, 2017, ReWalk Robotics announced that its innovative Restore soft exoskeleton system was featured in Medical Device & Diagnostic Industry magazine as one of the cutting-edge technologies seeking to help stroke survivors heal and retain critical motor skills. The article examines the latest advancements in technology for stroke-assistive medical devices and outlines the inspiration for a soft suit exoskeleton. Visit WallStEquities.com now and sign up for the free research on RWLK at: http://www.wallstequities.com/registration/?symbol=RWLK
Redwood City, California headquartered Avinger Inc.'s stock finished Monday's session 4.30% lower at $0.23 with a total trading volume of 340,513 shares. The stock is trading below their 50-day moving average by 23.07%. Shares of the Company, which designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease in the US and Europe, have an RSI of 36.96.
On November 09th, 2017, Avinger reported its results for Q3 2017. Total revenue was $2.1 million for Q3 2017; gross margin was -58%; and operating expenses were $7.7 million. Loss from operations for the quarter was $8.9 million, and adjusted EBITDA was a loss of $6.8 million. Cash and cash equivalents totaled $10.2 million as of September 30th, 2017. The free technical report on AVGR is available at: http://www.wallstequities.com/registration/?symbol=AVGR
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities